90 related articles for article (PubMed ID: 32154325)
1. Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study.
Brown ML; Motsch J; Kaye KS; File TM; Boucher HW; Vendetti N; Aggrey A; Joeng HK; Tipping RW; Du J; DePestel DD; Butterton JR; Paschke A
Open Forum Infect Dis; 2020 Mar; 7(3):ofaa054. PubMed ID: 32154325
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials.
Yang Q; Yang Y; He R; Yu B; Zhong Y; Lin F
Front Med (Lausanne); 2023; 10():1304369. PubMed ID: 38188339
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.
Sansone P; Giaccari LG; Di Flumeri G; Pace MC; Pota V; Coppolino F; Brunetti S; Aurilio C
Life (Basel); 2024 May; 14(5):. PubMed ID: 38792635
[TBL] [Abstract][Full Text] [Related]
4. Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury
Varache M; Rizzo S; Sayers EJ; Newbury L; Mason A; Liao CT; Chiron E; Bourdiec N; Jones A; Fraser DJ; Taylor PR; Jones AT; Thomas DW; Ferguson EL
RSC Pharm; 2024 Apr; 1(1):68-79. PubMed ID: 38646595
[TBL] [Abstract][Full Text] [Related]
5. Risk factor analysis for the occurrence of colistin-related nephrotoxicity: A retrospective observational cohort study.
He X; Fang J; Zhao J; Hu F; Lu Q; Bian X
Int J Antimicrob Agents; 2024 May; ():107232. PubMed ID: 38824972
[No Abstract] [Full Text] [Related]
6. Erratum in: IMI-Global Trends in Myopia Management Attitudes and Strategies in Clinical Practice-2022 Update.
Invest Ophthalmol Vis Sci; 2023 May; 64(5):12. PubMed ID: 37195658
[No Abstract] [Full Text] [Related]
7. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
[TBL] [Abstract][Full Text] [Related]
8. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
9. A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.
Campanella TA; Gallagher JC
Infect Drug Resist; 2020; 13():4297-4308. PubMed ID: 33268997
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
Kohno S; Bando H; Yoneyama F; Kikukawa H; Kawahara K; Shirakawa M; Aoyama N; Brown M; Paschke A; Takase A
J Infect Chemother; 2021 Feb; 27(2):262-270. PubMed ID: 33191112
[TBL] [Abstract][Full Text] [Related]
11. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
13. Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases.
Mushtaq S; Meunier D; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 Jan; 76(2):434-442. PubMed ID: 33152755
[TBL] [Abstract][Full Text] [Related]
14. Role of new antibiotics for KPC-producing Klebsiella pneumoniae.
Theuretzbacher U; Carrara E; Conti M; Tacconelli E
J Antimicrob Chemother; 2021 Jan; 76(Suppl 1):i47-i54. PubMed ID: 33534882
[TBL] [Abstract][Full Text] [Related]
15. Imipenem/Cilastatin/Relebactam Alone and in Combination against
Chen IH; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33139283
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
17. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637
[TBL] [Abstract][Full Text] [Related]
18. A review of the mechanisms that confer antibiotic resistance in pathotypes of
Nasrollahian S; Graham JP; Halaji M
Front Cell Infect Microbiol; 2024; 14():1387497. PubMed ID: 38638826
[TBL] [Abstract][Full Text] [Related]
19. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.
Zhang S; Liao X; Ding T; Ahn J
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534695
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Intravenous Colistin Monotherapy Versus Colistin Combined With Meropenem in Patients With Multidrug-Resistant Infections: A Retrospective Observational Study.
Baig M; Rahim S; Naseem Khan R; Memon DD; Ansari ZA; Athar Khan M
Cureus; 2023 Oct; 15(10):e47342. PubMed ID: 38022127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
